Back to top
more

Schwab U.S. Large-Cap Growth ETF: (SCHG)

(Delayed Data from NYSE) As of May 13, 2024 04:00 PM ET

$92.91 USD

92.91
932,344

0.00 (0.00%)

Volume: 932,344

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

After-Market: $92.94 +0.03 (0.03 %) 7:58 PM ET

Zacks News

Sweta Jaiswal, FRM headshot

Bet on Growth ETFs to Ride the US Economic Growth Optimism

Wall Street is expected to continue to gain on optimism surrounding new economic data and third-quarter earnings releases, which point to recovery from the pandemic-induced slowdown.

Sweta Jaiswal, FRM headshot

Here's Why Growth ETFs Are Attractive Bets Right Now

Wall Street is expected to continue gaining on optimism surrounding new economic data and third-quarter earnings releases, which point to recovery from the pandemic-induced slowdown.

Sweta Killa headshot

Large-Cap Growth ETF (SCHG) Hits New 52-Week High

This large-cap growth ETF hits a new 52-week high. Are more gains in store for this ETF?

Should Schwab U.S. LargeCap Growth ETF (SCHG) Be on Your Investing Radar?

Style Box ETF report for SCHG

Sweta Jaiswal, FRM headshot

Cathie Wood Projects Market Rotation to Growth: ETFs to Play

Let's take a look at some ETFs poised to win from Wood's prediction of market rotation to growth investing.

Sweta Jaiswal, FRM headshot

Growth ETFs Looking Great After an Impressive August

Investors can switch to growth-oriented areas of the market on optimism surrounding economic recovery and better-than-expected earnings for second-quarter 2021.

Sweta Jaiswal, FRM headshot

Tap the Current Market Momentum With These ETF Strategies

Here we discuss certain ETF strategies to help investors gain from optimism surrounding the recovering U.S. economy from the pandemic-led slump despite surging delta variant cases.

Sweta Jaiswal, FRM headshot

Growth ETFs to Bet on After a Decent July

Investors can switch to growth-oriented areas of the market on optimism surrounding the economic recovery and better-than-expected second-quarter 2021 earnings.

Sweta Jaiswal, FRM headshot

ETF Strategies to Cheer the Dovish Fed Minutes

Here we discuss certain ETF strategies to help investors gain from optimism surrounding the Fed's dovish stance amid recovering U.S. economy from the pandemic-led slump.

Sweta Jaiswal, FRM headshot

Try These ETF Strategies to Play the Market Optimism for 2H21

Here we discuss certain ETF strategies to help investors gain from the optimism surrounding the expectations of a strong Wall Street run in the second half of 2021.

Sweta Killa headshot

A Quick Guide to the 25 Cheapest ETFs

Keeping the importance of expense ratio in mind, we have highlighted the 25 cheapest ETFs currently on the market and have AUM of more than $50 million.

Sweta Jaiswal, FRM headshot

ETF Strategies to Play the Drop in New US COVID-19 Cases

Here we discuss some ETF strategies that investors can play amid the upbeat outlook for the U.S. market.

Sweta Jaiswal, FRM headshot

ETF Strategies to Play the US Market Optimism

Here we discuss some ETF strategies that investors can play amid the upbeat outlook for the U.S. market.

Sweta Jaiswal, FRM headshot

Growth ETFs to Gain From US Market Optimism in April

Strong fiscal stimulus support and improved coronavirus vaccine rollout are making a strong case in favor of faster U.S. economic recovery in 2021.

Sweta Jaiswal, FRM headshot

ETF Areas That Are Looking Attractive in April

Let's take a look at some ETF areas that are presenting some great investment opportunities for April considering the current market scenario.

Sanghamitra Saha headshot

Don't Let Underperformance in Growth ETFs Fool You

Focus on the technology sector, rising virus cases, talks of a hike in capital gains tax and still-low rates should bring the growth investing back in favor.

Sweta Jaiswal, FRM headshot

ETF Strategies to Gain From the Stimulus & Vaccine Optimism

Let's look at some ETF strategies to help investors gain from optimism surrounding another trench of coronavirus-aid package and coronavirus vaccine development.

Sanghamitra Saha headshot

ETFs to Win/Lose Amid Rising Inflationary Bets

Vaccine distribution and a likely fat federal spending bill under the Biden administration have led to a rise in future economic growth forecasts, which in turn boosted bets over rising inflation.

Sweta Killa headshot

A Bunch of Top-Ranked Growth ETFs Hitting New Highs (Revised)

Growth ETFs seem having more upside potential in the coming months, given a surging stock market and improving prospect of economic growth.

Sweta Killa headshot

A Bunch of Top-Ranked Growth ETFs Hitting New Highs

Growth ETFs seem having more upside potential in the coming months, given a surging stock market and improving prospect of economic growth.

Sweta Jaiswal, FRM headshot

Play These ETF Strategies to Ride the US Market Optimism

Let's look at some ETF strategies to help investors gain from optimism surrounding the chances of another trench of coronavirus-aid package and improved coronavirus vaccine rollout.

Sweta Jaiswal, FRM headshot

5 Growth ETFs to Gain on Stimulus & Vaccine Optimism

It is being believed that the chances of another trench of coronavirus-aid package and improved coronavirus vaccine rollout are making a strong case in favor of faster U.S. economic recovery in 2021.

Sweta Jaiswal, FRM headshot

ETF Strategies to Gain From US Market Optimism

Let's look at some ETF strategies to help investors gain from the optimism surrounding the coronavirus vaccine development as the outbreak continues to aggravate.

Sweta Jaiswal, FRM headshot

ETF Strategies to Gain From US Economic Data Optimism

Let's look at some ETF strategies to help investors gain from the upbeat U.S. economic data amid the coronavirus crisis.

Sweta Jaiswal, FRM headshot

ETF Strategies to Gain From Vaccine Progress, M&A Deals

ETF Strategies to Gain From Vaccine Progress, M&A Activities